Axsome Therapeutics (AXSM) PT Raised to $133 at UBS

UBS analyst Ashwani Verma raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $133.00 (from $105.00) while maintaining a Buy rating.

The analyst said, "We believe the regulatory de-risking from Alzheimer's Disease Agitation (ADA) indication in 2H25 & 2026 can provide fundamental upside. We raise our PT to $133 (from $105, see details below) and reiterate our Buy rating as we now see high likelihood of ADA filing acceptance and regulatory approval."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Boeing lands two U.S. defense contracts worth over $711M
• AI/ML Innovations plans $2M private placement on the CSE